Telomir Pharmaceuticals Analyst Price Targets - Benzinga

Telomir Pharmaceuticals Inc

TELONASDAQ

Trade with Public

Trade with Public

$1.09

-0.01-0.91%

마지막 업데이트: Oct 13, 4:00 PM

개요 뉴스 실적 전망 이벤트목표가재무 심리 지분 현황 비교 주식 보고서

Telomir Pharmaceuticals Analyst Price Targets - Benzinga

Telomir Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Telomir Pharmaceuticals (TELO).

Price Target Range — 1 Quarters

Analyst Consensus — 1 Analysts

1Buy

Consensus RatingBuy# Analysts1Avg. Consensus PT$4Upside to Avg. PT+267.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 17, 2026	Maxim Group	Jason McCarthy	Initiate	Buy	$4

Analyst Ratings News

PRO
Maxim Group Initiates Coverage On Telomir Pharmaceuticals with Buy Rating, Announces Price Target of $4

Maxim Group analyst Jason McCarthy initiates coverage on Telomir Pharmaceuticals (NASDAQ:TELO) with a Buy rating and announces Price Target of $4.

Benzinga Newsdesk

Stock Market Today: Dow Jones, Nasdaq 100, S&P 500 Futures Turn Green—Trilogy Metals, AMD, Applovin In Focus (UPDATED)

Editor’s Note: The future prices of benchmark tracking ETFs and lede were updated in the story.) US futures trimmed earlier losses to trade slightly above the flatline on Tuesday, following Monday’s mixed moves. Futures of major benchmark indices were trading higher.

Rishabh Mishra